Document Detail

Persistence of TEL-AML1 transcript in acute lymphoblastic leukemia in long-term remission.
MedLine Citation:
PMID:  12828580     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: It has recently been shown that t (12;21) (p13;q 22) is the most common molecular genetic abnormality in childhood acute lymphoblastic leukemia (ALL). We have analyzed this translocation in an attempt to evaluate its incidence and to monitor minimal residual disease (MRD) with t (12; 21) rearrangement by detection of TEL-AML1 transcript in patients with childhood ALL. PROCEDURE: All cryopreserved bone marrow samples were analyzed using a nested reverse transcription-polymerase chain reaction (RT-PCR) method. TEL-AML1 transcripts were searched for in 34 ALL patients, including six in relapse consecutively diagnosed at our institution between 1991 and 1997. RESULTS: TEL-AML1 transcripts were found in five (19%) of 27 patients with B precursor ALL. The patients with BCR-ABL, chromosome 11q23 rearrangement and T-ALL patients did not express TEL-AML1 transcripts. Moreover, MRD in five patients with TEL-AML1 transcripts were analyzed in serial samples. Although TEL-AML1 transcripts disappeared soon after the beginning of chemotherapy in three of the five patients, one patient continued to express them for up to 21 months without recurrence and remained in continuous complete remission for seven years after the cessation of chemotherapy. The remaining patient was admitted to our hospital after the second relapse but died following a failure to induce complete remission. CONCLUSION: For most patients, the presence of TEL-AML1 transcripts suggests excellent chemosensitivity and a favorable prognosis, but some patients with these transcripts have a different outcome. The present study suggests the possibility that a persistence of MRD is not necessarily related to a relapse of ALL with TEL-AML1 fusion. The prognostic significance of TEL-AML1 transcript remains controversial. Further studies are needed to evaluate the relation between the TEL-AML1 transcript and prognosis.
Chie Endo; Megumi Oda; Ritsuo Nishiuchi; Yoshiki Seino
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pediatrics international : official journal of the Japan Pediatric Society     Volume:  45     ISSN:  1328-8067     ISO Abbreviation:  Pediatr Int     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-06-27     Completed Date:  2003-10-14     Revised Date:  2008-05-21    
Medline Journal Info:
Nlm Unique ID:  100886002     Medline TA:  Pediatr Int     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  275-80     Citation Subset:  IM    
Department of Pediatrics, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Child, Preschool
Core Binding Factor Alpha 2 Subunit
Neoplasm Proteins / analysis,  genetics
Neoplasm, Residual
Oncogene Proteins, Fusion / genetics*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*,  pathology
Reverse Transcriptase Polymerase Chain Reaction
Sensitivity and Specificity
Translocation, Genetic*
Reg. No./Substance:
0/Core Binding Factor Alpha 2 Subunit; 0/Neoplasm Proteins; 0/Oncogene Proteins, Fusion; 0/TEL-AML1 fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Unrelated cord blood transplantation for second hemopoietic stem cell transplantation.
Next Document:  Evaluation of rebreathing potential on bedding for infant use.